Silence Therapeutics discloses separation terms for Craig Tooman in amended 8-K

Silence Therapeutics plc filed an amendment on July 16, 2026 to a Form 8-K originally filed December 15, 2025, adding details about compensation arrangements tied to the departure of Craig Tooman. The amendment supplements and amends Item 5.02 of the original filing to disclose information regarding material modifications to a compensatory plan or arrangement affecting a named executive officer, effected pursuant to an agreement entered into after the original filing.¹

The original filing had reported that, effective December 14, 2025, Craig Tooman agreed by mutual consent to end his employment with the company.¹ On July 10, 2026, the company and Tooman entered into a separation and release agreement.¹

Under that agreement, the company will provide Tooman salary continuation for 12 months following the separation date totaling $655,000, a one-time lump sum cash severance payment of $250,000, reimbursement of legal fees of $40,000 tied to negotiating the agreement, a lump sum bonus of $283,746.03 for 2025, healthcare premium reimbursement of $46,896.48, continued vesting of options under the company's 2023 Equity Incentive Plan and 2018 Long Term Incentive Plan through 45 days after the separation date, extended post-termination exercise periods of up to 24 months for 2023 Plan options and up to 12 months for 2018 Plan options, acceleration of unvested option vesting upon a change of control within 12 months of the separation date subject to compliance with the agreement, and up to $20,000 for fees owed to his tax providers.¹

The agreement also includes confidentiality, non-disparagement, non-solicitation and non-inference covenants along with a release of claims by Tooman.¹ The company said it intends to file the full separation agreement as an exhibit to its Quarterly Report on Form 10-Q for the quarter ended June 30, 2026.¹ The filing does not state Tooman's job title.